United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,238 shares of the stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $130.65, for a total value of $161,744.70. Following the transaction, the chief executive officer now directly owns 2,307 shares of the company’s stock, valued at $301,409.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of United Therapeutics Corporation (UTHR) opened at 128.45 on Friday. The company has a 50 day moving average price of $130.18 and a 200-day moving average price of $133.12. The stock has a market cap of $5.58 billion, a P/E ratio of 14.90 and a beta of 1.51. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.42 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Martine A. Rothblatt Sells 1,238 Shares of United Therapeutics Corporation (UTHR) Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/27/martine-a-rothblatt-sells-1238-shares-of-united-therapeutics-corporation-uthr-stock.html.

Several research firms have issued reports on UTHR. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. UBS AG restated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Jefferies Group LLC restated a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Six research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and a consensus price target of $134.50.

Hedge funds have recently added to or reduced their stakes in the stock. Wedge Capital Management L L P NC raised its stake in United Therapeutics Corporation by 2.7% in the first quarter. Wedge Capital Management L L P NC now owns 8,067 shares of the biotechnology company’s stock valued at $1,092,000 after buying an additional 213 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in United Therapeutics Corporation by 0.8% in the first quarter. Great West Life Assurance Co. Can now owns 111,167 shares of the biotechnology company’s stock valued at $15,046,000 after buying an additional 897 shares in the last quarter. Advisory Services Network LLC purchased a new stake in United Therapeutics Corporation during the first quarter valued at approximately $147,000. Advisor Partners LLC raised its stake in United Therapeutics Corporation by 6.4% in the first quarter. Advisor Partners LLC now owns 1,990 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 120 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in United Therapeutics Corporation by 123.8% in the first quarter. Canada Pension Plan Investment Board now owns 55,502 shares of the biotechnology company’s stock valued at $7,514,000 after buying an additional 30,700 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.